Latest Infectious Diseases News

Page 7 of 8
Recce Pharmaceuticals advances its clinical pipeline with expanded Phase 3 trials in Indonesia and Australia, backed by a $15.8 million capital raise and a $30 million debt facility.
Ada Torres
Ada Torres
31 July 2025
Island Pharmaceuticals has completed its acquisition of the broad-spectrum antiviral Galidesivir ahead of schedule, setting sights on expedited FDA approval leveraging the Animal Rule.
Ada Torres
Ada Torres
31 July 2025
Island Pharmaceuticals reported promising Phase 2a/b trial results for its dengue drug ISLA-101 and secured a strategic acquisition of the broad-spectrum antiviral Galidesivir, bolstering its pipeline and balance sheet.
Ada Torres
Ada Torres
24 July 2025
Genetic Signatures has formed a strategic partnership with Tecan and Repado to develop a fully automated, scalable infectious disease testing platform integrating advanced automation, compliant software, and proprietary assays.
Ada Torres
Ada Torres
22 July 2025
Atomo Diagnostics has successfully placed $260,000 of the shortfall from its recent Share Purchase Plan, issuing over 14 million shares and options to sophisticated investors. This capital injection strengthens the company’s working capital position as it advances its rapid diagnostic test business.
Ada Torres
Ada Torres
21 July 2025
Island Pharmaceuticals has accelerated its acquisition of the Galidesivir antiviral program from BioCryst Pharmaceuticals, adding a clinically advanced asset with significant US government backing and a promising regulatory pathway.
Victor Sage
Victor Sage
9 July 2025
Atomo Diagnostics has successfully closed a Share Purchase Plan and secured shareholder approval for a Tranche 2 Placement, raising a combined $1.53 million to support its ongoing operations.
Ada Torres
Ada Torres
27 June 2025
Invion Limited launches a Loyalty Option entitlement offer aimed at raising up to $16 million to support its advancing cancer clinical trials, including a promising anogenital cancer study with Peter MacCallum Cancer Centre.
Ada Torres
Ada Torres
13 June 2025
Island Pharmaceuticals has reported encouraging Phase 2a/b trial results for ISLA-101, demonstrating meaningful reductions in dengue viral load and symptoms in humans. The findings support further clinical development of this antiviral candidate.
Ada Torres
Ada Torres
12 June 2025
Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.
Ada Torres
Ada Torres
3 June 2025
Lumos Diagnostics has reached 50% recruitment of bacterial positive patients in its pivotal FebriDx CLIA waiver clinical study, setting the stage for a planned FDA submission in late 2025 and unlocking a substantial US market opportunity.
Ada Torres
Ada Torres
2 June 2025
Invion Limited reports no adverse events and early lesion reduction in its Phase I/II non-melanoma skin cancer trial, advancing to dose optimization.
Ada Torres
Ada Torres
29 May 2025

Browse the archive

Full archive